About the Company
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GILD News
Waltham cancer biotech unveils Gilead deal — and layoffs
A Waltham biotech is restructuring its team and reprioritizing its resources around two of its cancer drugs — including one ...
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license ...
Gilead's SNDA For Vemlidy Gets FDA Approval To Treat Chronic HBV Infection In Pediatric Patients
Gilead Sciences, Inc. (GILD) announced that the FDA has approved the supplemental new drug application or sNDA to expand ...
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer ...
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead ...
Gilead Sciences CEO's compensation soars to new heights
Gilead Sciences Inc. CEO Daniel O'Day total compensation rose 4.6% year over year to $22.6 million as the expanding cancer ...
Xilio stock jumps on Gilead Sciences license deal
Gilead Sciences signs exclusive license deal with Xilio Therapeutics for XTX301, an investigational tumor-activated IL-12 ...
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Gilead, Takeda Rumored to Have Sights on Iovance
The company appears to be a good fit for both Gilead Sciences Inc. (NASDAQ:GILD) and Takeda Pharmaceutical Co. (NYSE:TAK), as ...
Assembly Biosciences, Inc.: Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating inter ...
Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301
Gilead Sciences, Inc. (GILD) and Xilio Therapeutics, Inc. (XLO) announced an exclusive license agreement on Thursday to collaborate ...
Loading the latest forecasts...